GlassScriptPhysician profile
Mary Kate Murray
NPI 1811496144
$4,741.14
in general payments reported to CMS, 2019-2025
24 companies · $672 in 2025
The $672 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $587 · 2022: $468 · 2023: $690 · 2024: $2,324 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,685.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,260.93 | 2021-2025 | |
| Pfizer INC. | $753.77 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $411.58 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $354.16 | 2021-2024 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $339.46 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.38 | 2021-2025 | Xifaxan, Relistor, Plenvu |
| Intercept Pharmaceuticals, INC. | $178.13 | 2022-2025 | Ocaliva |
| Celgene Corporation | $150.70 | 2021-2024 | Zeposia |
| Amneal Pharmaceuticals LLC | $149.50 | 2024 | Crexont |
| Lilly USA, LLC | $127.94 | 2024-2025 | Omvoh, Mounjaro, Zepbound |
| Genzyme Corporation | $127.60 | 2023-2024 | |
| Ardelyx, INC. | $117.09 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $113.25 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $64.49 | 2021-2024 | Linzess |
| Aimmune Therapeutics, INC. | $61.60 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $60.31 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $48.41 | 2021-2024 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $47.78 | 2024 | Clenpiq, Rebyota |
| Gilead Sciences, INC. | $44.28 | 2024-2025 | |
| Novo Nordisk INC | $34.07 | 2023 | Wegovy |
| Tandem Diabetes Care, INC. | $32.87 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alfasigma USA, INC. | $28.53 | 2021 | |
| Nestle Healthcare Nutrition INC. | $24.89 | 2022 | |
| Daiichi Sankyo INC. | $16.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Kate Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.